Recent Updates
Recently added Catalysts
DXCM Positive Sentiment

Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign

Monday, November 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Dexcom, Inc. has launched 'A Letter to Diabetes' campaign to honor National Diabetes Awareness Month and World Diabetes Day. This initiative invites individuals affected by diabetes to share their personal stories, fostering a sense of community and support. The campaign aims to highlight diverse experiences and emotions related to living with diabetes.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of a community engagement campaign.
  • Encourages sharing personal diabetes stories.
  • Supports National Diabetes Awareness Month.
  • Promotes global awareness and connection.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes Day, creating a platform for people around the world to put into words everything they’ve wanted to say about their diabetes journey, from the heartfelt and humorous to the hopeful and unexpected.Throughout November, anyone touched by diabetes is invited to share their own letter to diabetes, includi

Frequently Asked Questions

What is the 'Letter to Diabetes' campaign?

It's a campaign by Dexcom inviting people to share their diabetes stories.

Why was the campaign launched?

It was launched to honor National Diabetes Awareness Month and World Diabetes Day.

Who can participate in the campaign?

Anyone touched by diabetes is invited to share their letters.

What types of stories can be shared?

Stories can range from heartfelt and humorous to hopeful and unexpected.

ShareAdd on Google
Tags: DXCM Dexcom diabetes awareness glucose biosensing diabetes community World Diabetes Day
Last updated: Nov 2, 2026

Biotech snapshot

Cash runway
$1818M liquidity · $0M/mo burn
Low dilution risk
Lead asset
The Seven Continuous Glucose Monitoring SystemPhase 1
Diabetes, Gestational →